- Home
- KIM vs UTHR Comparison
KIM vs UTHR Comparison
Compare KIM & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIM
- UTHR
- Stock Information
- Founded
- KIM 1958
- UTHR 1996
- Country
- KIM United States
- UTHR United States
- Employees
- KIM N/A
- UTHR N/A
- Industry
- KIM Real Estate Investment Trusts
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- KIM Real Estate
- UTHR Health Care
- Exchange
- KIM Nasdaq
- UTHR Nasdaq
- Market Cap
- KIM 14.7B
- UTHR 13.8B
- IPO Year
- KIM 1991
- UTHR 1999
- Fundamental
- Price
- KIM $21.21
- UTHR $313.13
- Analyst Decision
- KIM Buy
- UTHR Buy
- Analyst Count
- KIM 16
- UTHR 13
- Target Price
- KIM $24.41
- UTHR $382.00
- AVG Volume (30 Days)
- KIM 4.3M
- UTHR 691.8K
- Earning Date
- KIM 07-31-2025
- UTHR 07-30-2025
- Dividend Yield
- KIM 4.71%
- UTHR N/A
- EPS Growth
- KIM 56.53
- UTHR 17.94
- EPS
- KIM 0.82
- UTHR 25.63
- Revenue
- KIM $2,094,828,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- KIM $4.91
- UTHR $14.37
- Revenue Next Year
- KIM $3.23
- UTHR $6.59
- P/E Ratio
- KIM $25.78
- UTHR $12.22
- Revenue Growth
- KIM 10.16
- UTHR 17.62
- 52 Week Low
- KIM $17.93
- UTHR $266.98
- 52 Week High
- KIM $25.83
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- KIM 48.60
- UTHR 61.16
- Support Level
- KIM $21.00
- UTHR $292.34
- Resistance Level
- KIM $21.57
- UTHR $306.00
- Average True Range (ATR)
- KIM 0.46
- UTHR 9.55
- MACD
- KIM -0.03
- UTHR 1.92
- Stochastic Oscillator
- KIM 31.82
- UTHR 97.36
About KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.